quantisnow
FeedTopReportsPricing
⌘K
Live feed
00:15:15·625d
SECFiling
Cerevel Therapeutics Holdings Inc. logo

SEC Form EFFECT filed by Cerevel Therapeutics Holdings Inc.

CERE· Cerevel Therapeutics Holdings Inc.
Health Care
Original source

Companies

  • CERE
    Cerevel Therapeutics Holdings Inc.
    Health Care

Recent analyst ratings

  • Dec 8UpdateTD Cowen$45.00
  • Nov 20UpdateJP Morgan$25.00
  • Sep 28UpdatePiper Sandler$33.00
  • Aug 3UpdateBofA Securities$31.00
  • May 4UpdateWells Fargo$30.00
  • Apr 10UpdateTD Cowen-

Related

  • PR253d
    Alto Neuroscience Appoints Biotech Industry Veteran, Raymond Sanchez, M.D., to Its Board of Directors
  • SEC619d
    SEC Form 15-12G filed by Cerevel Therapeutics Holdings Inc.
  • SEC625d
    SEC Form EFFECT filed by Cerevel Therapeutics Holdings Inc.
  • SEC625d
    SEC Form EFFECT filed by Cerevel Therapeutics Holdings Inc.
  • SEC625d
    SEC Form EFFECT filed by Cerevel Therapeutics Holdings Inc.
  • INSIDER626d
    Former 10% Owner Pfizer Inc closing all direct ownership in the company (SEC Form 4)
  • 13D/G626d
    Amendment: SEC Form SC 13D/A filed by Cerevel Therapeutics Holdings Inc.
  • INSIDER626d
    Director Bain Capital Investors Llc returned 65,679,781 shares to the company (SEC Form 4)
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022